Self-reported data, such as age, sex, family history of MI or stroke, and cardiovascular symptoms, do not accurately predict elevated Lp(a) (≥50 mg/dL) as part of a screening process to prioritise people for Lp(a) testing and lipid lowering treatment (LLT).
This is the finding of an analysis of data from 24,994 individuals aged 50-65 years without diabetes from the population-based Swedish Cardiopulmonary BioImage Study (SCAPIS). The aim was to identify pragmatic strategies to maximize the immediate clinical impact of Lp(a) testing on the need for LLT in a primary prevention setting, given that testing availability is generally limited.
